Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias

NCT00749112 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Idiopathic Thrombocytopenic Purpura
Anemia, Hemolytic, Autoimmune

Interventions

DRUG: Alemtuzumab, Rituximab

Sponsor

Hospital Universitario Dr. Jose E. Gonzalez